Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 18/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18546978 | 0.89 | CYP11B1 (0.41) | CYP11B1CNR1CNR2CYP11B2 | |
| SCHEMBL18546999 | 0.85 | CYP11B1 (0.39) | CYP11B1CNR1CNR2CYP11B2 | |
| SCHEMBL18547174 | 0.85 | CYP11B1 (0.43) | CYP11B1CNR1CNR2CYP11B2 | |
| SCHEMBL18547172 | 0.85 | LRRK2 (0.42) | CYP11B1CNR1CNR2CYP11B2 | |
| SCHEMBL18547448 | 0.85 | CYP11B1 (0.43) | CYP11B1CNR1CNR2CYP11B2 | |
| SCHEMBL18547384 | 0.84 | CYP11B1 (0.38) | CYP11B1CNR1CNR2CYP11B2 | |
| SCHEMBL18547104 | 0.81 | CNR1 (0.45) | CYP11B1CNR1CNR2 | |
| SCHEMBL18576304 | 0.80 | CYP11B1 (0.40) | CYP11B1CNR1CNR2CYP11B2 | |
| SCHEMBL20689730 | 0.80 | CNR1 (0.45) | CYP11B1CNR1CNR2 | |
| SCHEMBL18547332 | 0.80 | CNR1 (0.45) | CYP11B1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| WO-2017035114-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | CYP11B1 123/4885CNR1 1/4885CNR2 3/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | CYP11B1 120/4885CNR1 1/4885CNR2 3/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | CYP11B1 120/4885CNR1 1/4885CNR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.